Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Icecure Medical Ltd ICCM

Healthcare Medical Care Medical Devices
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ICCM)

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

PR Newswire 20 hours ago

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

PR Newswire 1 day ago

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

PR Newswire 12 days ago

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

PR Newswire October 29, 2024

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

PR Newswire October 21, 2024

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

PR Newswire October 7, 2024

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

PR Newswire September 24, 2024

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

PR Newswire September 16, 2024

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

PR Newswire September 12, 2024
View More News ››

Opinion & Analysis (NDAQ:ICCM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ICCM)

IceCure Medical to Report Third Quarter 2024 Financial & Ope

BREAKING NEWS: $ICCM IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024IceCure...
whytestocks - 7 hours ago

IceCure Receives Notice of Allowance from U.S. Patent and Tr

JUST IN: $ICCM IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation...
whytestocks - October 21, 2024

IceCure Medical Requests Marketing Authorization to Treat Ea

News; $ICCM IceCure Medical Requests Marketing Authorization to Treat Early-Stage Breast Cancer from FDA2024-04-15 10:06:29 ET DENVER...
whytestocks - April 15, 2024

ICCM.....1st scalp of the a.m ; )

Call it "Lunch Money" 
Iseneschal - April 15, 2024

Fourth BRIIT Conference in India Features IceCure's ProSense

Breaking News: $ICCM Fourth BRIIT Conference in India Features IceCure's ProSense&#xAE; in Breast Cancer Imaging &...
whytestocks - February 27, 2024

An unbelievable N.R. and nothing.

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
billybob22 - February 27, 2024
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »